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HIV-positive children are possibly more prone to developing cholesteatoma. Chronic 
inflammation of the middle ear cleft may be more common in patients with HIV and 
this may predispose HIV-positive children to developing cholesteatoma. There are no 
studies that describe the radiological morphology of the middle ear cleft in HIV-
positive compared to HIV-negative children with cholesteatoma.  
 
Aim 
Compare the radiological differences of the middle ear cleft in HIV-positive and HIV-
negative children with cholesteatoma. 
 
Method 
A retrospective, cross-sectional, observational analytical review of patients with 
cholesteatoma at Red Cross War Memorial Children’s Hospital over a 6 year period.  
 
Results 
Forty patients were included in the study, 11 of whom had bilateral cholesteatoma and 
therefore 51 ears were eligible for our evaluation. HIV-positive patients had smaller 
(p=0.02) mastoid air cell systems (MACS). Forty percent of HIV-positive patients had 
sclerotic mastoids, whereas the rate was 3% in HIV-negative ears (p<0.02). Eighty-
two percent of the HIV-positive patients had bilateral cholesteatoma compared to 7% 
of the control group (p<0.02). There was no difference between the 2 groups with 
regards to aeration of the middle ear cleft, bony erosion of middle ear structures, 
Eustachian tube obstruction or soft tissue occlusion of the post-nasal space. 
 
Conclusion 
HIV-positive paediatric patients with cholesteatoma are more likely to have smaller, 
sclerotic mastoids compared to HIV-negative patients. They are significantly more 
likely to have bilateral cholesteatoma. This may have implications in terms of 
surveillance of HIV-positive children, as well as, an approach to management, 
recurrence and follow-up. HIV infection should be flagged as a risk factor for 
developing cholesteatoma.  
 10 
PART A: RESEARCH PROTOCOL 
 11 
 
Jessica Kate McGuire (MBBCh, FCORL) 
Registrar, Division of Otorhinolaryngology, Faculty of Health Sciences, 
University of Cape Town 
Johannes J Fagan (MBChB, FCORL, MMed) 
Professor and Chairman, Division of Otorhinolaryngology, Faculty of Health 
Sciences, University of Cape Town 
Supervisor: Tashneem Harris (MBChB, FCORL, MMed) 
Otolaryngologist, Division of Otolaryngology, University of Cape Town Faculty of 
Health Sciences 
 
Address for Correspondence 
Jessica Kate McGuire (MBBCh) 
Division of Otorhinolaryngology 
University of Cape Town 








Radiological Differences between HIV-Positive and 




Development of the mastoid air cell system (MACS) 
 
At 7 months’ gestation the bony spaces in the middle ear cleft are filled with 
mesenchyme. Regression and resorption of the mesenchyme and pneumatisation of 
the MACS proceed only if middle ear pressure is normal. Regression by apoptosis 
seems to be a pre-programmed event, occurring simultaneously with osteoclastic and 
osteoblastic bony remodelling to pneumatise the mastoid.1 
 
The mastoid antrum is the first recognisable mastoid air cell (MAC) and is completely 
formed at 34 weeks’ gestation. At birth there are usually no other air cells and the 
mastoid air cell system develops in three distinguishable phases from birth until 
puberty, when the MACS reaches its adult capacity (12cm2 by planimetric evaluation). 
The first phase occurs within the first year of life. There is rapid pneumatisation and 
the air cells increase the volume of the antrum by 1.5-2.5cm2 so that the total volume 
is 3.5-4cm2. The second phase occurs from 1 to 6 years of age and is characterised by 
a linear increase in aeration of 1-1.2cm2 per year. The final, slower phase continues 
into the third decade;2,3 thereafter it decreases substantially.3 This growth pattern 
seems to be mirrored in different ethnic populations .2 
 
The association between arrested pneumatisation and a small mastoid with middle ear 
pathology has long been accepted by otologists. Controversy exists whether mastoid 
aeration is genetically predetermined or whether environmental factors influence its 
formation. Proponents for genetic determination argue that in a large cohort of 
unselected mastoids, the aeration followed a normal bell shaped distribution.4 They 
also point out that measurements of MACS prior to and after the introduction of 
antibiotics did not demonstrate a difference.2 This is further supported by a study of 
children with secretory otitis media. All the children in the study had otitis media with 
effusion. Secretory otitis media may be preceded by acute otitis media and this study 
was designed to determine whether acute otitis media affects MAC pneumatisation. It 
involved two arms: in one arm the children had a history of preceding acute otitis 
media and the other arm they did not. The children with a history of acute otitis media 
showed normal development of their MACS; however the other group had smaller 
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MACS and a greater tendency to develop middle ear atelectasis.5 This study suggests 
that children who develop secretory otitis media without a preceding acute otitis media 
may be predisposed to negative middle ear pressure and hypoventilation due to their 
genetically programmed smaller MACS.5 
 
The counter argument of environmental factors influencing mastoid pneumatisation is 
endorsed by the finding that in children born through meconium stained amniotic 
fluid, there is a foreign body giant cell reaction in the middle ear mucosa. This results 
in granulation tissue formation, hyperplastic mucosa and secretions in the middle ear. 
The aeration and drainage pathways become blocked and may induce retraction 
pockets and predispose patients to recurring otitis media.6 This is further supported by 
a study of children with recurrent acute otitis media or otitis media with effusion in 
whom tympanostomy tubes were placed. They found that a small baseline MACS was 
associated with a young age at the time of first diagnosis of otitis media.7 Slow MACS 
growth was seen in children requiring multiple sets of ventilation tubes and a small 
final MACS size was a risk factor for chronic and recurrent infections.7 Animal studies 
also support the fact that chronic inflammation of the middle ear cleft causes 
hypocellularity of the MACS and increased thickness of the cortical bone.8 It is clear 
that chronic inflammation of the middle ear mucosa affects mastoid 
pneumatisation7,9,10. However it is still unclear whether Eustachian tube dysfunction 
plays a role.10 
 
The most likely explanation for varying MACS sizes seems to be that although 
genetically predetermined with a normal distribution of sizes in a population, 
pneumatisation of the mastoid is strongly influenced by environmental factors.1,11  
 
The middle ear and MACS may be considered a homogenous unit as diffusion of gases 
between the two areas is so rapid that significant differences between different areas 
of the middle ear cleft do not exist.12 The middle ear exchanges gases with two 
compartments: the nasopharynx via the Eustachian tube and blood through the middle 
ear mucosa.13 It seems these two systems work in a complementary fashion, where the 
mucosa is responsible for regulating small pressure changes and this is augmented 
periodically by the Eustachian tube to equalise higher pressure differences.14 It is 
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possible that a larger MACS requires less frequent openings of the Eustachian tube to 
maintain ambient pressure.15  
 
A mathematical model has been presented to establish the effect the MACS volume 
has on buffering middle ear pressure changes16 and clinically, this model showed that 
the MACS may serve as gas reservoir and regulate pressure changes in the middle 
ear.15 
Small MACS are associated with chronic ear disease but controversy exists as to 
whether it is the cause or the result of chronic inflammation. A radiological study of 
patients with unilateral cholesteatoma and a control group of normal patients revealed 
that in the patients with cholesteatoma; the MACS in both the affected and unaffected 
ears were smaller than the control group.17 A subsequent study echoed these 
sentiments and reported that patients with unilateral cholesteatoma have decreased 
pneumatisation and reduced patency of the Eustachian tube in the unaffected ear. The 
contralateral ear also had an increased risk of middle ear disease.18 This suggests that 
a small middle ear cleft makes one prone to cholesteatoma formation. 
 
Theories pertaining to the aetiopathogenesis of cholesteatoma formation 
 
1. The Invagination Theory 
This was originally proposed by Wittmaack and is the most widely accepted 
theory.19 The theory describes pars flaccida retraction pockets forming secondary 
to negative middle ear pressure and Eustachian tube dysfunction, repeated 
inflammation, small mastoid air cell volume or habitual sniffing. Retraction pocket 
advancement with accumulation of desquamated keratin results in cholesteatoma 
formation. Tos described cholesteatomas based on this theory as: (1) attic 
cholesteatoma arising from the pars flaccida; (2) tensa retraction cholesteatoma 
involving the entire pars tensa; and (3) sinus cholesteatoma, a localised postero-
superior retraction pocket extending into the sinus tympani.20 
 
2. The Immigration Theory 
Immigration theory describes cholesteatoma formation secondary to tympanic 
membrane epithelial migration or invasion through a defect in the tympanic 
membrane. It has been corroborated by animal studies.21 
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3. The Squamous Metaplasia Theory 
Chronic irritation and inflammation may cause pluripotent epithelial cells in the 
middle ear to become keratinising.22 
 
4. The Papillary Ingrowth Theory 
Keratin-filled microcysts or buds form in the basal layer of epithelium and 
invaginate into the middle ear. Retraction pockets and/or perforations are not a 
pre-requisite. This has been substantiated by clinical, experimental and animal 
studies.22 
 
Other factors that may contribute to cholesteatoma formation 
 
Age 
Cholesteatoma in children is considered to be more aggressive than in adults as it tends 
to be more extensive, causes greater ossicular chain pathology, has higher recurrence 
rates and is more difficult to eradicate.23-25 The causative factors in children are 
considered to be unstable and immature Eustachian tube function, higher rates of otitis 
media, and a temporal bone that is still developing.25 The epidemiology of acquired 
cholesteatoma is unclear; however, reduced incidence is associated with better access 
to primary care and improved social circumstances.23,24 
 
Socioeconomic 
In developing countries like South Africa, patients present with advanced disease and 
poor preoperative hearing thresholds. In a recent audit at our institution 8% of children 
presented with subperiosteal abscesses and a further 4% had intracranial sepsis.26 
Early diagnosis and surgical intervention could prevent these complications from 
occurring. Furthermore, hearing rehabilitation in resource limited settings can prove 
challenging as there is limited access to hearing aids, especially bone conduction 
hearing aids, making this a major public health concern.  
 
HIV 
Otological manifestations are commonly associated with Human Immunodeficiency 
Virus (HIV) infection. In a study of almost 1000 HIV-positive patients in India, 
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otological manifestations were present in 20% and chronic suppurative otitis media 
was present in 13%.27 Another study of children presenting to an otology clinic with 
chronic otorrhoea noted that cholesteatoma was present in 20% of children and over 
50% of the children were HIV-positive.28  
 
A recent audit at our institution showed 15% of children between the ages of 2-14 
years old with cholesteatoma were HIV-positive.26 The Western Cape Provincial 
prevalence rate of HIV is 1.1%.29 Although our sample size was small it raises an 
interesting question about whether HIV plays a role in the aetiology of cholesteatoma 
. Chronic inflammation of the middle ear cleft may be more common in patients with 
HIV and this may affect mastoid air cell pneumatisation and may predispose the 
children to developing cholesteatoma. To our knowledge there is very little literature 
available on cholesteatoma in HIV-positive patients. 
 
With this paper we hope to better describe and define the radiological manifestations 




The null hypothesis is that there are no radiological differences in pneumatisation of 
the MACS between HIV-positive and negative children with cholesteatoma.  
 
Aims and objectives 
 
The primary outcome is to determine whether there is a difference in mastoid 
pneumatisation in HIV-positive compared to HIV-negative children with 
cholesteatoma.  
 
Secondary outcomes are: establishing whether children with HIV develop 
cholesteatoma at a younger age, have more aggressive disease by radiological 
imaging, whether bilateral disease is more common and if Eustachian tube obstruction 




Research Design: Material and methods 
 
The study consists of a retrospective, cross-sectional, observational analytical review 
of patients with cholesteatoma at Red Cross War Memorial Children’s Hospital from 
2008-2015, and compares the radiological findings of children with HIV infection to 
those without HIV infection.  
 
A folder review will be done to obtain the following information: age at diagnosis, 
gender, HIV status and whether the child had unilateral or bilateral middle ear disease 
(including chronic mucosal disease) or cholesteatoma. We will examine their 
radiological images using the hospital’s digital imaging system.  
 
Inclusion criteria 
Patients with cholesteatoma who had had a computed tomography (CT) scan prior to 
their first surgical procedure will be included in the study. 
 
Exclusion criteria 
Patients in whom the HIV status is unknown. Patients who have craniofacial 
malformations, including cleft palate and Down’s syndrome will also be excluded. 
 
The following data were collected 
o Age at time of CT scan 
o Sex 
o Unilateral or bilateral disease (in which case, each ear was reviewed separately):  
o Patients who have chronic mucosal otitis media of the contralateral ear will also 
be documented, although the radiological changes of that ear will not be evaluated 
in the descriptive analysis 
o HIV status 
o Radiological features: 
a. Pneumatisation of the mastoid bone (descriptive and quantitative) 
 This will be documented as well, moderately, poorly pneumatised or 
sclerotic. 
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 It will be done independently by two investigators and the investigators 
will be blinded to the patients’ HIV status. The investigators will 
standardise their results. 
 One investigator will be an experienced otologist and one, a third year 
resident. 
 The mastoid air cell volumes of both the patients’ ears will be 
determined using Philips IntelliSpace Portal 7.0®, a computerised 
software programme utilised by the radiology department. The volume 
of the mastoid air cell spaces will be calculated by mapping the MACS, 
excluding the middle ear volume, in cubic millimetres (mm3). 
 For the purposes of accurate volume measurement, only CT temporal 
bone scans with 1mm cuts will be used. 
 The volumes will be calculated by 2 investigators, blinded to the HIV 
status of the patients. 
 To assess inter-rater reliability, each investigator will independently 
assess 10% of the other investigator’s sample. 
 A third investigator (also blinded to patient HIV status) will 
independently evaluate 10% of the entire sample. 
 One investigator will be a radiologist and one will be third year 
resident, an experienced otologist will be the third investigator. 
 The MAC volumes of all the ears will be calculated. 
b. Ventilation of the middle ear cleft 
c. Status of the ossicular chain 
d. Fallopian canal dehiscence 
e. Semicircular canal dehiscence 
f. Dehiscence of the tegmen 
g. Dehiscence of the posterior fossa 
h. Patency of the Eustachian tube 
i. Postnasal space patency at the level of the choana (coronal image) 






All statistical analyses will be performed using Stata version 12 (StataCorp, USA).  
Unpaired t-test or Wilcoxin rank sum tests (depending on the distribution) will be used 
to test for differences in continuous variables between HIV-positive and HIV-negative 
patients.  Fisher’s exact will test to determine whether there was an association 
between two categorical variables.   P<0.05 will be taken as the level for significance.  
 
To assess the relationship between size of MACS and HIV status we will perform 
simple linear regression and adjust for age using multivariable linear regression. The 
inter-rater agreement between rater’s measurements of MACS will be assessed using 
concordance correlation coefficient.  95% confidence intervals were reported with 




The findings of this paper will be the first paper in the literature on cholesteatoma to 
describe the radiological features of mastoid pneumatisation and bony erosion from 
cholesteatoma in children with HIV infection. It is an important paper because 




The findings from this paper will elucidate whether otological surveillance of children 
with HIV infection should include a heightened awareness for the possibility of 
cholesteatoma formation and its complications. 
 
Data safety and monitoring and privacy and confidentiality 
 
Only the principal investigator and supervisor will be able to collect data from the 
medical records. Radiological evaluation will be performed by the principle 
investigator, a radiologist and the supervisor. Information collected will be recorded 
on an electronic data sheet. The computer used for this purpose is password protected. 
Confidentiality will be maintained. 
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Risks and Benefits 
 
There is no direct benefit for the patients, however knowledge gained from this 




Ethics approval will be obtained from the Human Research Ethics Committee at the 
University of Cape Town.  
 
Informed Consent Process 
 




The expected time to collect the data for the study is 3 months. 
 
Dissemination of research 
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Cholesteatoma continues to be a major public health concern, especially in developing 
countries.1,2 The favoured model for its aetiopathology is the retraction pocket theory 
described by Tos.3 He surmised that chronic middle ear hypoventilation, with or 
without Eustachian tube dysfunction, may lead to pars flaccida retraction.3 As the 
retraction pocket advances, the neck becomes blocked by shed epithelial cells that are 
unable to migrate laterally and a cholesteatoma sac forms. Growth of the sac proceeds 
into the meso- and epitympanum and into the mastoid air cells (MAC).4 
 
The mastoid air cell system (MACS) serves as a gas reserve and regulates middle ear 
pressure changes.5 Consequently, patients with small MACS are predisposed to otitis 
media with effusion, not preceded or incited by an acute inflammatory process and 
have a greater tendency to develop negative middle ear pressure and atelectasis.6  
 
There is a definite association between hypocellularity of the MACS and 
cholesteatoma formation.7,8 A radiological study of patients with unilateral 
cholesteatoma and a control group of normal patients revealed that in the patients with 
cholesteatoma, the MACS in both the affected and unaffected ears were smaller than 
the control group.8-10 The side with the cholesteatoma had significantly decreased 
pneumatisation7,9-11 and reduced patency of the Eustachian tube compared to the 
unaffected ear.7 The contralateral ear also had an increased risk of middle ear 
disease.7,9 This suggests that a small middle ear cleft makes one prone to 
cholesteatoma formation. 
 
Although it is controversial whether MACS development is genetically 
predetermined, or whether environmental factors play a role, increasingly more studies 
suggest a genetic predisposition strongly influenced by environmental factors as 
evidenced by the above findings.7-10 Likewise, the epidemiology of acquired 
cholesteatoma is unclear but reduced incidence is associated with better access to 







The aims of this review are to evaluate the literature on MACS pneumatisation to 
assess what factors are involved in its final determination. 
 
Literature Search Strategy 
 
PubMed was searched using the following search terms: 
 Mastoid pneumatisation (pneumatization) AND genetics 
 Mastoid pneumatisation (pneumatization) AND hereditary factors 
 Mastoid pneumatisation (pneumatization) AND acquired factors 
 Poor mastoid pneumatisation (pneumatization) AND acquired factors 
 Mastoid pneumatisation (pneumatization) AND inflammation 
 Mastoid pneumatisation (pneumatization) AND infection 
 Mastoid pneumatisation (pneumatization) AND Human Immune Virus 
 Mastoid pneumatisation (pneumatization) AND acquired factors 
 Mastoid pneumatisation (pneumatization) AND size 
 Mastoid pneumatisation (pneumatization) AND cholesteatoma 
 Mastoid pneumatisation (pneumatization) AND chronic otitis media 
 Mastoid pneumatisation (pneumatization) AND Eustachian tube dysfunction 
 Chronic otitis media AND hypocellular mastoid 
 Mastoid development AND pneumatisation (pneumatisation) 
 Middle ear AND gas exchange 
 HIV AND atopy 
 HIV AND adenoidal hypertrophy 
 HIV AND Eustachian tube dysfunction 





Papers were included that described the process of mastoid pneumatisation or the 
factors affecting mastoid pneumatisation. It included animal studies and laboratory 
temporal bone studies. Studies on middle ear gas exchange, its importance and the 




Papers that were not in English were excluded, as well as papers exploring 
pneumatisation and tympanoplasty surgery.  
 
Interpretation of Literature 
 
Genetically pre-programmed pneumatisation of the MACS induces regression and 
resorption of the mesenchyme that initially fills the middle ear cleft, by apoptosis. This 
proceeds simultaneously with osteoclastic and osteoblastic bony remodelling.13. There 
is evidence to show that apoptosis of osteoblasts is significantly suppressed in the face 
of chronic inflammation of the middle ear cleft. Osteoblast apoptosis may be an 
essential step for bone resorption in MAC pneumatisation.14 
 
Not only may the MACS vary within a population;15 it may even differ between the 2 
mastoid processes of a single individual.16 The air cell system may encompass the 
whole mastoid process as well as other parts of the temporal bone, or it may be 
acellular or hypocellular.16  
 
Morphology of Mastoid Hypocellularity 
 
The different types of mastoid hypocellularity may be distinguished using a 
combination of macroscopic, radiological and histomorphological investigations, 
allowing for a detailed analysis of the architecture and relationship of the pneumatised 
and non-pneumatised portions of the mastoid.16 Types 1 and 2 hypocellularity 
represent a primary hypocellular condition with incomplete pneumatisation during 
development augmented by environmental factors, whereas Type 3 hypocellularity 
represents a secondary hypocellular condition as a result of bony obliteration from 
chronic infection (namely mastoiditis) post MAC development. 16 
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Type 1 hypocellularity is characterised by 2 main features. Firstly: there is no clear 
boundary between the pneumatised and non-pneumatised portions of the bone, and the 
two parts are connected by openings of different sizes and it is not always possible to 
distinguish air cells from marrow spaces. Secondly: the non-pneumatised bone is 
substantially different from normal spongy bone and the thickened trabecular bone 
decreases the size of the marrow spaces. 16 
 
Type 2 hypocellularity portrays a well-defined boundary between the pneumatised and 
non-pneumatised mastoid portions. The boundary may be slightly sclerotic but the 
architecture of the non-pneumatised spongy bone is not altered. 16 
 
Type 3 hypocellularity consists of normal pneumatisation of large parts of the 
temporal bone, with a hypocellular mastoid process. The air cells in the mastoid are 
confined to its upper portion. There is a clear distinction between the pneumatised and 
diploic (apical) parts, which are separated by dense bone. Bone architecture in the 
spongy apical bone shows almost normal architecture.16  The dense bone is not 
composed of compact, sclerotic bone; but fine, densely packed trabeculae filling the 
former air cells; probably caused by bony remodelling and proliferation. 16 
 
It may be difficult to distinguish between the types of hypocellularity radiologically. 
Type 3 hypocellularity represents an end-stage form of chronic mastoiditis by bony 
remodelling. A single mastoid may portray a combination of either Type 1 or 2 with 
Type 3 hypocellularity. 16 
 
Various theories dominate the literature regarding the aetiopathophysiology of the 
hypocellular mastoid process.  
 
Genetic theory of mastoid hypocellularity 
 
The argument for genetic determination of the variations of MACS pneumatisation in 
the population was introduced by a large cohort of unselected mastoids, where the 
aeration followed a normal bell shaped distribution.15 Additionally, it has been noted 
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that measurements of MACS prior to and after introduction of antibiotics did not 
demonstrate a difference.17  
 
This argument is further supported by a study of children with secretory otitis media. 
All the children in the study had otitis media with effusion. Secretory otitis media may 
be preceded by acute otitis media and this study was designed to determine whether 
acute otitis media affects MAC pneumatisation. It involved two arms: in one arm the 
children had a history of preceding acute otitis media and the other arm did not. The 
children with a history of acute otitis media showed normal development of their 
MACS; however the other group had smaller MACS and a greater tendency to develop 
middle ear atelectasis.6 This study suggests that children who develop secretory otitis 
media without a preceding acute otitis media may be predisposed to negative middle 
ear pressure and hypoventilation due to their genetically programmed smaller MACS.6 
 
Another study compared the sizes of MACS in children and their parents; as well as 
the MACS sizes in dizygotic and monozygotic twins. They found there to be a 
significant correlation between the sizes of the children’s MACS and that of their 
parents, if their parents had similarly sized MACS. This result lends further support to 
the argument of genetic predetermination of MACS size.18 However, if the parents 
had dissimilarly sized MACS, there was no correlation between the parents’ MACS 
size and that of their offspring. 18 In those cases, the children’s MAC volume agreed 
with one or other parent or had a value somewhere in-between that of their parents18, 
suggesting perhaps that MACS size is a complex trait and that genetic susceptibility 
may well be mediated by a host of environmental factors. Not mentioned in the paper, 
is that the children and parents obviously shared the same environmental space. 
Consequently factors like overcrowding, malnutrition, poor access to health care 
services and sanitation would apply equally to each individual family and therefore 
environmental factors may well affect families concordantly, influencing the similar 
size of their MACS. Alternatively, there may have been some social movement 
amongst the parents prior to them having their children and this may account for the 
discordance in their MACS size. 
 
An early review of the inheritance of the pneumatisation of bone examined the 
literature on MACS aeration in monozygotic and dizygotic twins and found there to 
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be greater concordance in monozygotic compared to dizygotic twins. However, these 
studies did not use an objective or calculable method to assess the MACS and this is 
a great limitation to their findings.18 Dahlberg and Diamant explored the similarities 
of MACS sizes between monozygotic and dizygotic twins, using planimetric X-ray 
films to measure the pneumatisation more objectively and again found greater 
concordance among monozygotic twins.15,18 The MACS sizes in dizygotic twins 
varied in much the same way as the general population. 18 Considering that dizygotic 
twins are raised in the same milieu, the difference in MACS size may be accounted 
for by genetic inheritance. However, the variation between the parents and their 
offspring was less than the variation between dizygotic twins, suggesting that foetal 
and perinatal factors may play a significant role.18 Using their results from the twin 
studies, they suggested that inheritance is 1.56 times more influential than 
environmental factors when determining MACS size. 18 
 
Development of the mastoid air cell system 
 
Development of the MACS is well described: at 7 months gestation the bony spaces 
in the middle ear cleft are filled with mesenchyme. Regression and resorption of the 
mesenchyme and pneumatisation of the MACS proceed only if middle ear pressure is 
normal.13 Development of the MACS occurs in three distinguishable phases from birth 
until puberty when the MACS reaches its adult capacity (12cm2 by planimetric 
evaluation). The first phase occurs within the first year of life. There is rapid 
pneumatisation and the air cells increase the volume of the antrum by 1.5 - 2.5cm2 so 
that the total volume is 3.5 - 4cm2. The second phase occurs from 1 to 6 years old and 
is characterised by a linear increase in aeration of 1 - 1.2cm2 per year. The final, slower 
phase continues into the third decade,17,19 thereafter it decreases substantially.19 This 
growth pattern seems to be mirrored in different ethnic populations.17 
 
It seems reasonable to deduce that any pathophysiological insult occurring within the 
phases of development may affect the final outcome of MACS size.  
 
Mucosal inflammation and the environmental theory of mastoid hypocellularity 
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Children born through meconium stained amniotic fluid may have perinatally induced 
toxic contamination of the middle ear cleft with amniotic fluid cellular content. This 
causes a foreign body reaction and initiates a giant cell reaction. Granulation tissue 
and pseudocysts block the ventilatory routes of the middle ear. The trapped secretions 
may inhibit resistance to infection and an ongoing cycle of inflammation, granulation 
tissue and obstruction ensues.20 
 
The effect of middle ear mucosal inflammation inhibiting mastoid pneumatisation was 
illustrated by an animal study where paraffin liquid was instilled into the left tympanic 
cavity a few days after birth. The experimental side was markedly hypocellular and 
sclerotic compared to the control side in all cases.21 Similarly, glycerine was instilled 
unilaterally in 4 groups of piglets at different time intervals after birth. Pneumatisation 
was inhibited in all the experimental ears and the later the initiation of the 
inflammatory process, the less the degree of pneumatisation suppression. They 
concluded that chronic inflammation inhibits pneumatisation. The study also 
illustrates that the point in time during development of the mastoid at which the 
inflammation begins plays an important role in the final determination of mastoid 
size.22 
 
A radiological study of patients between the ages of 1 and 18 years old with otitis 
media (with and without effusion) found that patients without an effusion had greater 
age-matched MACS. However the size of the MACS in this group of patients did show 
great variability and this suggests a genetic cause. On the other hand, a large 
percentage of the group of patients with an effusion had a MACS volume <5 millilitres 
(cm3) and the conclusion was made that not only the timing of the disease, but also the 
duration may impact on final MACS.23 
 
These discoveries were explored clinically, and researchers corroborated their findings 
that a greater degree of mucosal inflammation was associated with lower middle ear 
total pressure and a smaller area of mastoid air cells.24 The corollary for this finding 
is that an intervention performed during mastoid development for patients with 
mucosal inflammation may halt or reverse pneumatisation suppression.25 They tested 
this clinically by inserting ventilation tubes into the tympanic membrane, collecting a 
mucosal specimen at the time of the procedure, and monitoring pneumatic space 
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volume. Their findings echoed their previous results. However, mucosal oedema 
resolved within 2 months of treatment and the pneumatisation process was re-initiated 
in patients with severe inflammation after 1.5 - 2 years.25 This is a strong argument for 
the environmental theory of mastoid pneumatisation and more particularly highlights 
the findings by Wittmaack in the early twentieth century.26 
 
A more recent study of the benefit of ventilation tubes for otitis media with effusion 
(OME) after a 5 year follow-up period showed that a smaller MACS size was 
associated with multiple episodes of OME and multiple ventilation tube placements.27 
Obviously children requiring multiple sets of ventilation tubes have persistent OME 
and ongoing inflammation.27 It does raise the question as to the natural history and 
treatment of OME in preventing suppression of mastoid growth. Is it a self-limiting 
condition, or does ventilation tube placement stimulate the recovery process? It 
appears that OME following an episode of acute otitis media (AOM) and AOM in 
themselves do not predispose to small MACS.6 
 
Atopic rhinitis represents a chronic inflammatory disorder affecting the respiratory 
epithelium of the nasal cavity and paranasal sinuses. It seems appropriate to assume 
the same disorder may affect the respiratory epithelium of the middle ear cleft, with 
allergens gaining access to the middle ear via the Eustachian tube. Recently it was 
shown that atopic individuals had smaller MACS volumes compared to control 
patients. They were also 4 to 5 times more likely to have an abnormal tympanogram 
(type B or type C).28 It is a subject that needs to be explored further; but the concept 
of atopy induced otitis media is a perfect example of a genetic predisposition initiated 
by environmental triggers affecting final MACS size. 
 
Human immunodeficiency virus 
 
There is some controversy as to whether patients infected with HIV have a higher 
prevalence of allergic disease.29,30 There may be an association between a higher CD8-
positive cell count and the prevalence of symptomatic allergic disease.29 The 
mechanism behind this is that CD8- positive cells stimulate Immunoglobulin-E (Ig-E) 
synthesis,29 which may predispose these patients to an atopic phenotype. 
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However, it is unclear whether the raised IgE levels are caused by HIV infection or 
whether they are the result of atopy,31 and considering that atopy is a common 
condition, the probability of dual pathology is high.30 A recent prospective study of 
HIV-positive and negative children in South Africa showed no significant difference 
in skin prick test positivity between the 2 groups.30 However, there was a higher 
prevalence of chronic rhinitis in the HIV positive patients, possibly caused by 
immunological dysfunction.30-32  
 
Chronic inflammation of the middle ear cleft may be more common in patients 
infected with HIV and this may affect mastoid air cell pneumatisation and may 
predispose the children to developing cholesteatoma. In a study of almost 1000 HIV-
positive patients in India, otological manifestations were present in 20% and chronic 
suppurative otitis media was present in 13%.33 Another study of children presenting 
to an otology clinic with chronic otorrhoea noted that cholesteatoma was present in 
20% of children and over 50% of the children were HIV-positive.1 However, there are 
no studies available that describe mastoid development in children born with HIV.  
 
Role of the Eustachian tube 
 
The physiological function of the MACS is that of middle ear pressure regulation. It 
seems as though normal pressure is maintained in the middle ear by the complimentary 
actions of the MACS and the Eustachian tube. The MACS is responsible for 
maintaining homeostasis through constant regulation of small pressure changes and 
the Eustachian tube augments this with intermittent regulation of higher pressure 
changes.34,35 In periods of transient or persistent Eustachian tube dysfunction and 
negative middle ear pressure; a larger MACS delays the advent OME secondary to 
middle ear mucosal haemorrhage.35,36 
 
Animal models show that in ears with normal functioning mucosa, occlusion of the 
Eustachian tube does not impair MAC pneumatisation. Presumably this is because 
normal middle ear mucosa allows gas exchange to proceed independently of the 
Eustachian tube and maintain a normal pressure environment, such as is required for 
pneumatisation to occur.37,38  
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Eustachian tube dysfunction in the presence of mucosal inflammation 
 
Problems arise in the presence of mucosal inflammation. Whether or not Eustachian 
tube dysfunction contributes to poor MAC pneumatisation in this setting is 
controversial. There is evidence to show that both Eustachian tube occlusion39 and a 
patulous Eustachian tube40 are associated with smaller MAC volumes. However, there 
is also evidence to show no correlation between auditory tube occlusion and poor 
mastoid pneumatisation.41 Unfortunately the technique used to assess auditory tube 
patency in this study was not able to determine whether the Eustachian tubes were 
patulous. It is possible that both an occluded and a patulous Eustachian tube are the 
result, rather than the cause of general inflammation of the respiratory mucosa in the 
upper respiratory tract. However, this is difficult to measure clinically and perhaps 
laboratory based studies may shed further light on this theory. 
 
Eustachian tube dysfunction, adenoidal hypertrophy and HIV-infection 
 
HIV is active in the lymphoid tissue throughout the period of clinical latency.42 
Adenoidal size in HIV-positive children with good immunological function has been 
shown to be greater than that of a cohort of HIV-negative control patients.42 However, 
HIV- positive children with poor immunological status have significantly smaller 
adenoidal tissue compared to the control group.42 The differences in size correlated 
with the clinical progression of the disease and may be used as a prognostic marker.42 
 
Identification of Needs for Further Research 
 
Further histologic and longitudinal clinical studies are needed to clarify the outcome 
after contamination of the middle ear space by amniotic fluid cells in terms of 
susceptibility to chronic inflammation and/or infection of the middle ear and final 
MACS. 
 
More research regarding HIV and mastoid pneumatisation is required. Considering 
that otological conditions manifest commonly in these patients, pneumatisation may 
be arrested. There is scant research on HIV and cholesteatoma. HIV is prevalent in 
Sub-Saharan Africa and studies elucidating whether there is an association between 
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HIV infection and cholesteatoma formation may alter the necessity of otological 
surveillance in this population. 
 
The area of atopy and allergy induced inflammation of the middle ear cleft also 
requires further evaluation, especially considering that there is an increasing 
prevalence of atopy in developed countries43 which may impact on otological health. 
The rise of atopy has been attributed to altered antimicrobial exposure and an early 
antibiotic debut (<24 months), particularly if exposed to cephalosporins or 
erythromycin.43 A proposed mechanism for antibiotic induced susceptibility to atopy 
is that they alter the normal microflora of the gut, which are essential in normal 
immune programming.44 
 
There may be a benefit in sampling middle ear mucosa in atopic children to see 
whether it shows eosinophilic inflammation. Future efforts aiming to address whether 
MAC development may benefit from regular anti-allergy therapy in the pre-pubertal 
period might constitute a new guideline for the treatment of otitis media in atopic 
individuals.  
 
There is no literature available on whether radiotherapy of the head and neck region 
as a child affects mastoid pneumatisation. There is also no literature on whether 
chronic inflammatory diseases, like cystic fibrosis affect mastoid pneumatisation. It is 
well documented that children with cystic fibrosis have poor development of their 
paranasal sinuses but they seemingly do not have an increased incidence of chronic 
ear disease. Since pneumatisation is arrested by inflammation of the mucosa, one 
would expect both radiotherapy and chronic inflammatory conditions of the upper 
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HIV-positive children are possibly more prone to developing cholesteatoma. Chronic 
inflammation of the middle ear cleft may be more common in patients with HIV and 
this may predispose HIV-positive children to developing cholesteatoma. There are 
no studies that describe the radiological morphology of the middle ear cleft in HIV-
positive compared to HIV-negative children with cholesteatoma.  
 
Aim 
Compare the radiological differences of the middle ear cleft in HIV-positive and HIV-
negative children with cholesteatoma. 
 
Method 
A retrospective, cross-sectional, observational analytical review of patients with 
cholesteatoma at Red Cross War Memorial Children’s Hospital over a 6 year period.  
 
Results 
Forty patients were included in the study, 11 of whom had bilateral cholesteatoma 
and therefore 51 ears were eligible for our evaluation. HIV-positive patients had 
smaller (p=0.02) mastoid air cell systems (MACS). Forty percent of HIV-positive 
patients had sclerotic mastoids, whereas the rate was 3% in HIV-negative ears 
(p<0.02). Eighty-two percent of the HIV-positive patients had bilateral 
cholesteatoma compared to 7% of the control group (p<0.02). There was no 
difference between the 2 groups with regards to aeration of the middle ear cleft, bony 
erosion of middle ear structures, Eustachian tube obstruction or soft tissue occlusion 
of the post-nasal space. 
 
Conclusion 
HIV-positive paediatric patients with cholesteatoma are more likely to have smaller, 
sclerotic mastoids compared to HIV-negative patients. They are significantly more 
likely to have bilateral cholesteatoma. This may have implications in terms of 
surveillance of HIV-positive children, as well as, an approach to management, 
recurrence and follow-up. HIV infection should be flagged as a risk factor for 




HIV-positive children are possibly more prone to developing cholesteatoma.1 
Cholesteatoma continues to be a major public health concern, especially in developing 
countries.1,2 The favoured model for its aetiopathology is the retraction pocket theory 
describe by Tos.3 He surmised that chronic middle ear hypoventilation, with or without 
Eustachian tube dysfunction, may lead to pars flaccida retraction. As the retraction 
pocket advances, the neck becomes blocked by shed epithelial cells that are unable to 
migrate laterally and a cholesteatoma sac forms. Growth of the sac proceeds into the 
meso- and epitympanum and into the mastoid air cells (MAC).4 
 
The mastoid air cell system (MACS) serves as a gas reservoir and regulates middle 
ear pressure changes.5 Consequently, patients with small MACS are predisposed to 
otitis media with effusion, not preceded or incited by an acute inflammatory process, 
and have a greater tendency to develop negative middle ear pressure and atelectasis.6 
There is a definite association between hypocellularity of the MACS and 
cholesteatoma formation.7,8 
 
Radiological evaluation of patients with unilateral cholesteatoma compared to a 
control group of normal patients revealed that in patients with cholesteatoma, the 
MACS in both the affected and unaffected ears were smaller than the control group.8-
10 The side with the cholesteatoma had significantly decreased pneumatisation7,9-11 and 
reduced patency of the Eustachian tube compared to the unaffected ear.7 The 
contralateral ear also had an increased risk of middle ear disease.7,9 This suggests that 
a small middle ear cleft makes one prone to cholesteatoma formation. 
 
Although it is controversial whether MACS development is genetically 
predetermined, or whether environmental factors play a role, increasingly more studies 
suggest a genetic predisposition strongly influenced by environmental factors as 
evidenced by the above findings.7-10 
 
Otological manifestations are commonly associated with Human Immunodeficiency 
Virus (HIV) infection. In a study of almost 1000 HIV-positive patients in India, 
otological manifestations were present in 20% and chronic suppurative otitis media 
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was present in 13%.12 Another study of children presenting to an otology clinic with 
chronic otorrhoea noted that cholesteatoma was present in 20% of children and over 
50% of the children were HIV-positive.2 
 
Chronic inflammation of the middle ear cleft may be more common in patients with 
HIV infection and this may affect mastoid air cell pneumatisation and may predispose 
the children to developing cholesteatoma. However, there are no studies available that 
describe mastoid development or radiological features in children born with HIV 
infection.  
 
This study aims to compare the radiological differences of the middle ear cleft in HIV-
positive and HIV-negative children with cholesteatoma. The primary outcome is to 
determine whether there is a difference in mastoid pneumatisation. Secondary 
outcomes are: establishing whether children with HIV infection develop 
cholesteatoma at a younger age, have more aggressive disease by radiological 
imaging, whether bilateral disease is more common and if Eustachian tube obstruction 
is more prevalent. 
  
Material and methods 
 
The study is a retrospective, cross-sectional, observational analytical review of 
patients with cholesteatoma at Red Cross War Memorial Children’s Hospital from 
2008-2015, comparing the radiological findings of children with HIV to those without 
HIV.  
 
Patients with cholesteatoma who had a high resolution computed tomography (CT) 
scan prior to their first surgical procedure were included in the study. There was a 
change in policy between 2008 and 2015, requiring patients to have radiological 
imaging prior to surgery and consequently, not all patients had radiological imaging 
prior to surgery. Patients in whom the HIV status was unknown, patients who had 




Both folder review and analysis of the electronic radiological images were necessary 
to obtain the information: age at diagnosis, sex of the patient, HIV status and whether 
the child has unilateral or bilateral middle ear disease (chronic otitis media, either 
mucosal disease or cholesteatoma), unilateral or bilateral cholesteatoma. The 
radiological features noted were: 
 Size of the MACS (mm³) 
 Pneumatisation of the mastoid bone (descriptive) 
o Good 
o Moderate 
o Poor  
o Sclerotic 
o Cannot comment 
 Ventilation of the middle ear cleft 
o Aerated 
o Opacification of middle ear and mastoid 
o Opacification of the middle ear 
o Opacification of mastoid air cells 
o Cannot comment  
 Status of the ossicular chain 
o Present 
o Malleus and incus present 
o Malleus present 
o Nil 
 For each of the structures below we commented on whether the bony structure was 
intact, dehiscent or could not comment: 
o Fallopian canal dehiscence 
o Semicircular canal dehiscence 
o Dehiscence of the tegmen tympani 
o Dehiscence of the posterior fossa 
 Patency of the Eustachian tube 






Only CT temporal bone scans with cuts not more than 1 millimeter (mm) thick were 
used for accuracy purposes. This excluded 6 patients in whom the cuts were too large. 
Of the 34 patients whose MAC volumes were calculated, the ear of 1 patient was not 
included because it had been previously operated on. In each patient the volumes of 
both ears were calculated.  
 
The MAC volumes were determined using Philips IntelliSpace Portal 7.0®, the 
computerised software programme utilised by our radiology department. The volume 
of the mastoid air cell spaces was calculated by mapping the MACS, excluding the 
middle ear volume, in cubic millimetres (mm3) (Image 1). The volumes were 
calculated by 2 investigators (a radiologist and a third year otolaryngology resident), 
blinded to the HIV status of the patients. To assess inter-rater reliability, each 
investigator independently assessed 10% of the other investigator’s sample. A third 
investigator (an experienced otologist, also blinded to patient HIV status) then 
independently evaluated 10% of the entire sample.  
 
 









Pneumatisation was categorised as well, moderately, poorly pneumatised or sclerotic. 
This was done independently by two investigators (an experienced otologist and a 
third year otolaryngology resident) and the investigators were blinded to the patients’ 
HIV status. The investigators standardised their results. Aeration of the middle ear 
cleft was categorised into 4 categories: aerated, opacified middle ear and mastoid, 
opacified middle ear only and opacified mastoid only. The ossicular chain was 
assessed to be present, malleus and incus present, malleus present only or absent. 
 
We were unable to obtain sagittal reconstruction images on all the patients. There is 
no accepted method for measuring the adenoidal pad in the postnasal space using 
coronal or axial CT scan images. The Eustachian tube cartilage lies in a groove 
between the petrous temporal bone and the greater wing of the sphenoid bone. This 
groove ends opposite the centre of the medial pterygoid plate at the level of the 
choanae. We chose to measure the patency of the postnasal space at this level using 
axial images. We graded the soft tissue occlusion of the post-nasal space as <50%, 51-




All statistical analyses were performed using Stata version 12 (StataCorp, USA).  We 
used unpaired t-test or Wilcoxin rank sum tests (depending on the distribution) to test 
for differences in continuous variables between HIV-positive and HIV-negative 
patients.  We used Fisher’s exact test to determine whether there was an association 
between two categorical variables.   P<0.05 was taken as the level for significance.  
 
To assess the relationship between size of MACS and HIV status, we performed 
simple linear regression and adjusted for age using multivariable linear regression. 
The inter-rater agreement between raters’ measurements of MACS was assessed using 
concordance correlation coefficient.  95% confidence intervals were reported with 






Fifty-nine patients and 74 ears with cholesteatoma were seen in the department from 
2008 to 2015 (Table 1). Twenty percent of the patients were HIV-positive and the HIV 
status was unknown in 7% of the patients. Forty patients met both the inclusion and 
exclusion criteria, 11 of whom had bilateral cholesteatoma and therefore 51 ears were 
eligible for our evaluation. There was a male to female predominance (7:3). Only 1 
HIV-positive patient was not on highly active antiretroviral therapy (HAART). The 
age range in the HIV-positive and negative groups were similar (p=0.45): 3 to 11 and 
3 to 13 years old, respectively (mean of 7 and 8 years old, respectively). There was no 
significant difference between the HIV-positive and negative groups in terms of sex, 





Cholesteatoma Number of Ears 
Number of patients 59 
 
74 
HIV-positive patients 12 (20%) 9 21 
HIV-negative patients 43 (73%) 6 49 
HIV-status unknown 4 (7%) 
  
Patients with CT Scans 40 
 
51 
Table 1: Summary of the number of patients seen in the department 2008 to 2015 
 
 
Total HIV Negative (%) HIV Positive (%) P Value 
Number of ears 51 31 20  
Number of patients 40 29 (72.5%) 11 (27.5%)  
Sex 
   
0.70 
Male 28 (70%) 21 (72%) 7 (64%)  
Female 12 (30%) 8 (28%) 4 (36%)  
Age 
   
0.45 
Range 3 – 13  3 – 13  3 – 11   
Median (interquartile range) 4 4 5  
Mean  7,85 8 7,1  
Side    0.39 
Left 21 (41%) 11 (35%) 10 (50%)  
Right 30 (59%) 20 (65%) 10 (50%)  
Table 2: Patient demographics 
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Relatively more HIV-positive patients had poorly pneumatised or sclerotic mastoids: 
40% of the HIV-positive ears had sclerotic MACS, whereas the rate was 3% in HIV-
negative ears. This finding was significant at p<0.02 (Image 2 and 3). Significantly 
more HIV-positive patients had bilateral middle ear disease (p<0.001) and 82% of 
HIV-positive patients had bilateral cholesteatoma compared to 7% of the control 
group (p<0.05). There was no significant difference between the 2 groups with regards 
to opacification of the middle ear cleft.   There was also no significant difference with 
regard to the number of patients who had ossicular chain erosion, Fallopian canal 
dehiscence, semicircular canal dehiscence, tegmen dehiscence, or posterior fossa 
dehiscence. Patients with HIV infection did not have significantly more Eustachian 
tube obstruction or postnasal space occlusion (Table 3). 
 
  
Image 2 and 3: The smaller, more sclerotic mastoid of an HIV-positive (left) compared 













Total HIV Negative (%) HIV Positive (%) P value 
Pneumatisation of mastoid 
   
<0,02 
Good 3 (6%) 3 (10%) 0  
Moderate 16 (31%) 14 (45%) 2 (10%) 
 
Poor 14 (27%) 7 (23%) 7 (35%)  
Sclerotic 9 (17%) 1 (3%) 8 (40%)  
Cannot comment 9 (17%) 6 (20%) 3 (15%)  
Bilateral middle ear disease 21 (53.5%) 10 (34.5%) 11 (100%) <0,001 
Bilateral cholesteatoma 11 (27.5%) 2 (7%) 9 (82%) <0,05 
Opacification 
   
0,72 
Ossicular chain 
   
0,37 
Fallopian canal 
   
1.00 
SCC 
   
1.00 
Tegmen 
   
0,63 
Posterior fossa 
   
0,15 
Eustachian tube 
   
0,08 
Postnasal space soft tissue 
occlusion of postnasal space 
   
0,11 
Table 3: Results establishing whether there is a relationship between HIV and the 
outcome variable assessed 
 
There was a significant difference between the volumes of the MACS in the two 
groups (Table 4) (p<0.02). Although age was considered a strong clinical confounder 
for MACS, HIV status was independently associated with MACS (in cholesteatoma 
affected ears) with HIV-positive patients having significantly lower volumes than their 
HIV-negative counterparts (-386mm3 (95% CI -59; -713), p=0.022). 
 
Table 4: Volume differences between HIV-positive and HIV-negative MACS 
 
Concordance correlation coefficients indicate that there was excellent agreement 
between the investigators (Table 5). 















Negative 27 1101.3 577.8 1054.2 648.5 1260.3 327.2 2679.8 










Twenty percent of the patients seen in the department between 2008 and 2015 were 
HIV-positive. Although this is a small sample group, it is much higher than the 
Western Cape Province prevalence rate of HIV infected children in the same age group 
which was 1.1% in 2008.13 The age range in both the HIV-positive and negative 
groups were similar, indicating that these children present to specialist services at a 
similar age. However, it is unclear whether the total duration of their disease is more 
protracted as the finding of poorly pneumatised or sclerotic mastoids might suggest. 
It is recognised that otorrhoea is poorly managed and underestimated at a primary 
health care level and many patients spend years under their supervision prior to 
referral.1 
 
Development of the MACS 
 
There is a significant difference in both mastoid pneumatisation (p<0.02) and MACS 
size (p=0.02) between HIV-positive and negative patients, even when we adjust for 
age.  Development of the MACS is well described: at 7 months’ gestation the bony 
spaces in the middle ear cleft are filled with mesenchyme. Regression and resorption 
of the mesenchyme and pneumatisation of the MACS proceed only if middle ear 
pressure is normal.14 Development of the MACS occurs in 3 distinguishable phases 
from birth until puberty when the MACS reaches its adult capacity (12cm2 by 
planimetric evaluation).  
 
The first phase occurs within the first year of life: there is rapid pneumatisation; 
followed by a period of linear growth and an increase in aeration from 1 to 6 years old 
and a final, slower phase that continues into the third decade.15,16  
 Rho (95% CI) 
Investigator 1 and 2 0.995 (0.984, 0.998) 
Investigator 1 and 3 0.990 (0.951, 0.998 
Investigator 2 and 3 0.993 (0.977, 0.998) 
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The process is genetically programmed but is strongly influenced by environmental 
factors.7-10 Any inflammatory insult occurring within the phases of development may 
affect the final outcome of MACS size.17 Both the timing and the duration of the 
inflammation impact on the final determination of mastoid size.18-19 It is thought the 
trapped secretions may inhibit resistance to infection and an ongoing cycle of 
inflammation, granulation tissue and obstruction ensues.20  
 
The mastoid air cell system (MACS) serves as a gas reserve and regulates middle ear 
pressure changes.5 Consequently, patients with small MACS are predisposed to otitis 
media with effusion, not preceded or incited by an acute inflammatory process and 
have a greater tendency to develop negative middle ear pressure and atelectasis.6 There 
is a definite association between hypocellularity of the MACS and cholesteatoma 
formation.7-8 
 
Patients with HIV infection have chronic inflammatory otological disease,2,12 this 
manifests as more HIV positive patients having poorly pneumatised or sclerotic 
mastoids (p<0.02) and may predispose them to developing cholesteatoma. The 
aetiology of their chronic middle ear disease is unclear but suppurative diseases are 
often associated with lower CD4-positive counts, while tympanic membrane retraction 
and otitis media with effusion are linked to higher CD4-positive counts.21 
 
Aetiopathogenesis of Cholesteatoma 
 
There are 4 theories pertaining to the aetiopathogenesis of cholesteatoma formation:22 
 
The Invagination Theory 
This was originally proposed by Wittmaack and is the most widely accepted theory.23 
The theory describes pars flaccida retraction pockets forming secondary to negative 
middle ear pressure and Eustachian tube dysfunction, repeated inflammation, small 
mastoid air cell volume or habitual sniffing. Retraction pocket advancement with 
accumulation of desquamated keratin results in cholesteatoma formation. Tos 
described cholesteatomas based on this theory as: (1) attic cholesteatoma, arising from 
the pars flaccida; (2) tensa retraction cholesteatoma, involving the entire pars tensa; 
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and (3) sinus cholesteatoma, a localised postero-superior retraction pocket extending 
into the sinus tympani.3 
 
This may explain why HIV-positive patients more commonly have mucosal disease 
of the other ear (p<0.001); and why they more often have bilateral cholesteatomata 
(p<0.05) compared to HIV negative children. They also have smaller (p=0.02) poorly 
pneumatised or sclerotic MAC (p<0.02), which may promote the formation of 
localised retraction pockets and encourage cholesteatoma formation. It is 
understandable that there was no significant difference between the two groups in 
terms of opacification of the middle ear cleft because all of the patients had active 
squamous disease. 
 
The Immigration Theory 
Immigration theory describes cholesteatoma formation secondary to tympanic 
membrane epithelial migration or invasion through a defect in the tympanic 
membrane.22 Considering that active mucosal disease manifests so commonly in HIV-
positive patients,2,12 it seems entirely possible that cholesteatoma may occur secondary 
to epithelial migration into the middle ear cleft. 
 
The Squamous Metaplasia Theory 
Chronic irritation and inflammation may cause pluripotent epthithelial cells in the 
middle ear to become keratinising.22 Patients with HIV infection have more than 1 
reason to have chronic inflammation of the middle ear cleft: smaller (p=0.02), poorly 
pneumatised or sclerotic mastoids (p<0.02) and active mucosal disease.2 
 
HIV infection is also associated with immune dysregulation and another possibility is 
chronic atopic mucosal inflammation. There is some controversy as to whether 
patients with HIV have a higher prevalence of allergic disease.24,25 There may be an 
association between a higher CD8-positive cell count and the prevalence of 
symptomatic allergic disease.24 The mechanism behind this is that CD8-positive cells 
stimulate Immunoglobulin-E (Ig-E) synthesis,24 which may predispose these patients 
to an atopic phenotype. 
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However, it is unclear whether the raised IgE levels are caused by HIV or whether 
they are the result of atopy,26 and considering that atopy is a common condition, the 
probability of dual pathology is high.25 A recent prospective study of HIV-positive 
and negative children in South Africa showed no significant difference in skin prick 
test positivity between the 2 groups.25 However, there was a higher prevalence of 
chronic rhinitis in the HIV positive patients, possibly caused by immunological 
dysfunction.25-27 It is possible that the inflammation is not only limited to the nasal 
cavities but that it involves the middle ear cleft too. A limitation of our study is that 
we did not assess whether our patients had concurrent atopic disease. 
 
The Papillary Ingrowth Theory 
Keratin-filled microcysts or buds form in the basal layer of epithelium and invaginate 
into the middle ear. Retraction pockets and/or perforations are not a pre-requisite. This 
has been substantiated by clinical, experimental and animal studies22 but it is difficult 
to justify how this theory might predispose HIV-positive patients to cholesteatoma 
formation. 
 
There was no significant relationship between having HIV infection and having bony 
erosion of important structures in the middle ear, compared to HIV-negative children. 
Various factors are responsible for the aggressiveness of cholesteatoma. Inflammation 
is crucial. Inflammatory cytokines induce fibroblasts to secrete cytokines that are 
essential in the differentiation, proliferation and migration of matrix keratinocytes.22 
Inflammatory cytokines also promote angiogenesis, which is necessary for continued 
migration of keratinocytes into the middle ear.22 Recent studies show that squamous 
epithelium becomes destructive when subjected to a chronically infected 
environment.22 All these factors suggest that once the cholesteatoma is established in 
both HIV-positive and HIV-negative children, the inflammatory process rendered by 
the disease and concurrent infection predict its aggressiveness, rather than HIV 
infection itself influencing its course. 
 
HIV Infection and Eustachian Tube Dysfunction 
 
The physiological function of the MACS is that of middle ear pressure regulation. It 
seems as though normal pressure is maintained in the middle ear by the complimentary 
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actions of the MACS and the Eustachian tube. The MACS is responsible for 
maintaining homeostasis through constant regulation of small pressure changes and 
the Eustachian tube augments this with intermittent regulation of higher pressure 
changes.28,29 In periods of transient or persistent Eustachian tube dysfunction and 
negative middle ear pressure; a larger MACS delays the advent of otitis media with 
effusion secondary to middle ear mucosal haemorrhage.29,30 
 
Animal models show that in ears with normal functioning mucosa, occlusion of the 
Eustachian tube does not impair MAC pneumatisation. Presumably this is because 
normal middle ear mucosa allows gas exchange to proceed independently of the 
Eustachian tube and maintain a normal pressure environment, such as is required for 
pneumatisation to occur.31,32  
 
Problems arise in the presence of mucosal inflammation. Whether or not Eustachian 
tube dysfunction contributes to poor MAC pneumatisation in this setting is 
controversial. There is evidence to show that both Eustachian tube occlusion33 and a 
patulous Eustachian tube34 are associated with smaller MAC volumes. However, there 
is also evidence to show no correlation between auditory tube occlusion and poor 
mastoid pneumatisation.35 Unfortunately the technique used to assess auditory tube 
patency in the above study was not able to determine whether the Eustachian tubes 
were patulous. It is possible that both an occluded and a patulous Eustachian tube are 
the result, rather than the cause of general inflammation of the respiratory mucosa in 
the upper respiratory tract. However, this is difficult to measure clinically and perhaps 
laboratory based studies may shed further light on this theory.  
 
Although our results show no relationship between HIV status and Eustachian tube 
occlusion (p=0.08), there are a couple of limitations to our study. Firstly, the 
Eustachian tube is a dynamic tube and CT scan analysis is a static investigation so it 
may not accurately portray how the Eustachian tube is functioning. Secondly, patients 
may have a waxing and waning course of Eustachian tube obstruction and this would 
not be revealed in the CT scan examination. Further investigations are warranted to 
determine Eustachian tube function over time in patients with chronic middle ear 
disease, especially in HIV positive patients. 
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Although the majority of articles site the cartilaginous portion of the Eustachian tube 
as the obstruction point,36 there is new evidence to show that the previously 
overlooked protympanic segment of the Eustachian tube may be responsible for tubal 
obstruction. 36 The Eustachian tube is cone-shaped and the nasopharyngeal portion has 
a larger aperture than the tympanic aperture. 36 The narrowest part of the tube lies at 
the junction of the proximal bony ⅓ and the distal cartilaginous ⅔ of the tube, known 
as the isthmus. It stands to reason that mucosal inflammation and recurrent infection 
of the middle ear may occlude the narrow lumen of the proximal bony portion of the 
Eustachian tube. 36 Otological infections are well recognised to be associated with HIV 
infection2,12 and this may contribute to Eustachian tube dysfunction. It is equally 
plausible that inflammation may ascend from the nasal cavities to involve the mucosa 
of the Eustachian tube.  
  
There was no apparent connection between adenoidal size and HIV infection. A 
limitation to our study is that we did not include the viral load or CD4+ counts and 
therefore we are unable to determine whether the children were virally suppressed or 
whether they had treatment failure. HIV is active in the lymphoid tissue throughout 
the period of clinical latency.37 Adenoidal size in HIV-positive children with good 
immunological function has been shown to be greater than that of a cohort of HIV-
negative control patients. 37 However, HIV-positive children with poor immunological 
status had significantly smaller adenoidal tissue compared to the control group. 37 We 





The aetiopathogenesis of cholesteatoma is complicated. HIV-positive paediatric 
patients with cholesteatoma are more likely to have smaller, poorly pneumatised or 
sclerotic mastoids compared to HIV-negative patients. They are significantly more 
likely to have bilateral cholesteatoma and bilateral middle ear disease. This may have 
implications in terms of surveillance of HIV-positive children, as well as an approach 
to management, recurrence and follow-up. HIV infection should be flagged as a risk 
factor for developing cholesteatoma and a high index of suspicion should be 
maintained when examining an HIV-positive child with chronic otorrhoea. This paper 
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highlights deficiencies in the literature, where further research is warranted to gain a 
clearer understanding of why these patients have altered MAC development and why 
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Number Age Sex 
HIV 
status HAART Side 
Unilateral/ 
bilateral 




0 No 0 right 1 Unilateral 0 
    Male 1 Positive 1 Yes 1 left 2 Bilateral 1 
              
              
31914799 8 1 0 0 1 1 
87805693 8 1 0 0 2 1 
86055209 12 1 0 0 1 1 
115665028 5 1 0 0 2 1 
15376312 6 1 0 0 1 1 
38036034 6 1 0 0 2 0 
88034772 6 1 0 0 2 0 
13297965 6 1 0 0 1 0 
88615125 8 1 0 0 2 0 
43790385 4 1 0 0 1 1 
11479011 6 1 0 0 2 0 
14673875 10 2 0 0 1 1 
14673875 10 2 0 0 2 1 
114285778 13 1 0 0 1 0 
86759727 12 1 0 0 1 0 
28718393 3 1 0 0 1 1 
28718393 3 1 0 0 2 1 
38769386 9 1 0 0 1 0 
16248262 5 2 0 0 1 0 
89150502 4 2 0 0 1 0 
88726633 8 1 0 0 1 0 
113377675 12 2 0 0 1 0 
119057602 6 1 0 0 1 1 
12813085 10 1 0 0 1 0 
87650545 10 2 0 0 2 0 
43754555 9 2 0 0 1 1 
15890775 9 1 0 0 1 0 
86587870 10 1 0 0 2 0 
106743875 12 2 0 0 1 0 
88908884 7 2 0 0 1 1 
86587870 11 1 0 0 2 0 
86376597 11 1 1 1 2 1 
86376597 11 1 1 1 1 1 
86419157 5 1 1 1 1 1 
86419157 5 1 1 1 2 1 
22901359 6 2 1 1 1 1 
34771162 3 1 1 1 1 1 
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34771162 3 1 1 1 2 1 
88512322 11 1 1 1 2 1 
88512322 11 1 1 1 1 1 




112185244 10 2 1 1 2 1 
88465638 9 1 1 1 2 1 
88465638 9 1 1 1 1 1 
24701732 8 2 1 1 2 1 
24701733 9 2 1 1 1 1 
116422718 6 1 1 0 1 1 
116422718 6 1 1 0 2 1 
22901359 6 2 1 1 2 1 
15536105 4 1 1 1 2 1 
15536105 4 1 1 1 1 1 
 





well - 1 
sclerotic tip - 
1 
opacification 
- ME + 
mastoid - 2 present - 1  
dehiscent - 
1 
mod - 2 marrow - 2 
opacification 
- Middle ear - 
1 MI - 2 intact - 0 
poor - 3 both - 3 aerated - 0 m - 3   
extensive dx - 4 neither - 4 
opacification 
- mastoid not 
ME - 3 nil - 4   
sclerotic - 5   3 1 1 
3 3 0 1 0 
1 4 2 1 1 
2 4 3 2 0 
2 4 2 2 1 
3 2 1 1 1 
4 1 3 3 1 
4 1 3 4 1 
2 2 3 1 1 
4 1 1 1 1 
1 1 2 2 1 
cant comment  2 1 1 
3 1 2 1 0 
3 1 3 3 1 
2 2 2 1 1 
3 1 2 1 0 
2 2 2 1 1 
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2 2 2 1 1 
2 1 2 1 1 
2 1 1 4 1 
3 3 2 1 1 
2 1 3 2 1 
5   4 1 
cant comment  2 1 1 
2 3 2 1 1 
2 1 3 1 0 
3 1 2 2 1 
1 1 2 1 1 
2 2 3 3 1 
2 1 2 1 1 
2 1 2 3 0 
done  2 3 0 
2 2 2 4 1 
2 2 2 1 1 
5  2 1 1 
5  2 1 1 
5  2 1 1 
3 3 2 4 1 
3 3 2 1 1 
5  3 1 0 
5     
prev operated 1 2 4 1 
3 1 3 2 1 
3 2 3 2 1 
5  2 2 1 
3 1 2 2 1 
3 1 1 4 1 
5  2 3 1 
5  2 1 1 
3 3 2 4 0 










intact 0 intact 0 occluded 0 no - 0  
dehiscence 1 
dehiscence 
1 patent 1 yes - 1  
         
         
0 0 1 0 80% 
0 0 1 0 cant comment 
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0 1 1 0 >60% 
0 0 1 0 moderate 
0 0 1 0 moderate 
0 0 1 0 60% 
0 0 1 0 100% 
0 0 0 0 90% 
0 0 1 0 cant comment 
0 0 0 0 <50% 
1 0 0 0 
huge - does not 
touch septum 
0 0 0 0 
huge - does not 
touch septum 
0 0 0 0 mod 
0 0 1 0 
huge - touch 
septum 
0 0 0 0 huge 
0 0 0 0 50% 
0 0 0 0 50% 
0 0 0 0 75-80% 
1 0 1 0 <25% 
0 0 1 0 50% 
0 0 0 0 <50% 
0 0 1 0 50% 
0 0 1 0 100% 
0 0 1 0 unable to assess 
0 0 0 0 50% 
0 0 1 0 <50% 
0 0 1 0 huge 
0 0 0 0 50% 
0 0 1 1 small 
0 0 0 0 cant comment 
0 0 0 0 80% 
0 0 0 0 80% occlusion 
0 1 0 0 80% occlusion 
0 0 0 0 50% 
0 0 0 0 50% 
0 0 1 0 100% 
0 1 0 1 moderate 
0 0 0 0 moderate 
0 0 0 0 does not go down 
1 0 1 0 does not go down 
     
0 0 0 0 50% 
0 0 1 0 20% 
0 0 1 0 20% 
0 0 0 0 40% 
0 0 0 0 40% 
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0 0 0 0 huge 
0 0 0 0 huge 
0 0 1 0 100% 
1 0 0 0 small 
0 1 0 0 small 
 




cubmm Left Cholesteatoma 
31914799 8 1 0 507,8 482,6 R 
43790385 4 1 0 971,2 1131,4 R 
28718393 3 1 0 522,2 1090,9 RL 
119057602 6 1 0 1485,4 1241 R 
86587870 11 1 0 403,8 655,1 L 
86055209 12 1 0 980,6 8600 R 
115665028 5 1 0 4530,2 1545,2 L 
15376312 6 1 0 678,4 1278,5 R 
38036034 6 1 0 1018,2 2679,8 L 
88034772 6 1 0 1841,4 1099,8 L 
13297965 6 1 0 1162,9 1713,7 R 
88615125 8 1 0 1567,2 1111,7 L 
11479011 6 1 0 2992,5 1792,4 L 
14673875 10 2 0 591 1054,2 RL 
114285778 13 1 0 2127,5 5300 R 
86759727 12 1 0 379,1 963,2 R 
38769386 9 1 0 1199,7 7300 R 
16248262 5 2 0 648,5 371,8 R 
89150502 4 2 0 327,2 779,9 R 
88726633 8 1 0 1260,3 3342,6 R 
113377675 12 2 0 1065,4 1575,6 R 
12813085 10 1 0 628,5 6300 R 
87650545 10 2 0 5500 895,6 L 
43754555 9 2 0 2248,4 2145 R 
15890775 9 1 0 1027,6 1597,6 R 
86376597 11 1 1 415,6 223,2 RL 
86419157 5 1 1 605,3 740 RL 
22901359 6 2 1 547,6 609,4 L 
34771162 3 1 1 532,5 1438,2 RL 
88512322 11 1 1 1072 1128,3 RL 
112185244 10 2 1 x 1232,6 RL 
88465638 9 1 1 736,1 572,3 RL 
24701732 8 2 1 317 413,8 RL 







































Adjusted multiple regression: adjusted for age 
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For Full Length Articles (Research Papers) a structured abstract, by means of 
appropriate headings (e.g. Objectives, Methods, Results, Conclusion), should 
provide the context or background for the research and should state its purpose, basic 
procedures (selection of study subjects or laboratory animals, observational and 
analytical methods), main findings (giving specific effect sizes and their statistical 
significance, if possible), and principal conclusions. It should emphasize new and 
important aspects of the study or observations. Abstracts for Case Reports should not 
exceed 100 words and should not have a structured format. Abstracts for Review 
Papers may be structured or non-structured depending on author preference. 
Subdivision - numbered sections  
Divide your article into clearly defined and numbered sections. Subsections should 
be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in 
section numbering). Use this numbering also for internal cross-referencing: do not 
just refer to 'the text'. Any subsection may be given a brief heading. Each heading 
should appear on its own separate line. 
Introduction  
State the objectives of the work and provide an adequate background, avoiding a 
detailed literature survey or a summary of the results. 
Material and methods  
Provide sufficient detail to allow the work to be reproduced. Methods already 
published should be indicated by a reference: only relevant modifications should be 
described. 
Results  
Results should be clear and concise. 
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Discussion  
This should explore the significance of the results of the work, not repeat them. A 
combined Results and Discussion section is often appropriate. Avoid extensive 
citations and discussion of published literature. 
Conclusions  
The main conclusions of the study may be presented in a short Conclusions section, 
which may stand alone or form a subsection of a Discussion or Results and 
Discussion section. 
Appendices  
If there is more than one appendix, they should be identified as A, B, etc. Formulae 
and equations in appendices should be given separate numbering: Eq. (A.1), Eq. 
(A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and 
figures: Table A.1; Fig. A.1, etc. 
Essential title page information  
 
• Title. Concise and informative. Titles are often used in information-retrieval 
systems. Avoid abbreviations and formulae where possible. 
• Author names and affiliations. Please clearly indicate the given name(s) and 
family name(s) of each author and check that all names are accurately spelled. 
Present the authors' affiliation addresses (where the actual work was done) below the 
names. Indicate all affiliations with a lower-case superscript letter immediately after 
the author's name and in front of the appropriate address. Provide the full postal 
address of each affiliation, including the country name and, if available, the e-mail 
address of each author. 
• Corresponding author. Clearly indicate who will handle correspondence at all 
stages of refereeing and publication, also post-publication. Ensure that the e-mail 
address is given and that contact details are kept up to date by the 
corresponding author. 
• Present/permanent address. If an author has moved since the work described in 
the article was done, or was visiting at the time, a 'Present address' (or 'Permanent 
address') may be indicated as a footnote to that author's name. The address at which 
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the author actually did the work must be retained as the main, affiliation address. 
Superscript Arabic numerals are used for such footnotes. 
Keywords  
 
Immediately after the abstract, provide a maximum of 6 keywords, using American 
spelling and avoiding general and plural terms and multiple concepts (avoid, for 
example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly 
established in the field may be eligible. These keywords will be used for indexing 
purposes. 
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Collate acknowledgements in a separate section at the end of the article before the 
references and do not, therefore, include them on the title page, as a footnote to the 
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(e.g., providing language help, writing assistance or proof reading the article, etc.). 
Formatting of funding sources  
List funding sources in this standard way to facilitate compliance to funder's 
requirements: 
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Units  
Follow internationally accepted rules and conventions: use the international system 
of units (SI). If other units are mentioned, please give their equivalent in SI. 
Footnotes  
Footnotes should be used sparingly. Number them consecutively throughout the 
article. Many word processors can build footnotes into the text, and this feature may 
be used. Otherwise, please indicate the position of footnotes in the text and list the 
footnotes themselves separately at the end of the article. Do not include footnotes in 
the Reference list. 
Artwork 
Electronic artwork  
General points 
• Make sure you use uniform lettering and sizing of your original artwork.  
• Embed the used fonts if the application provides that option.  
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New 
Roman, Symbol, or use fonts that look similar.  
• Number the illustrations according to their sequence in the text.  
• Use a logical naming convention for your artwork files.  
• Provide captions to illustrations separately.  
• Size the illustrations close to the desired dimensions of the published version.  
• Submit each illustration as a separate file. 
A detailed guide on electronic artwork is available. 
You are urged to visit this site; some excerpts from the detailed information are 
given here. 
Formats 
If your electronic artwork is created in a Microsoft Office application (Word, 
PowerPoint, Excel) then please supply 'as is' in the native document format.  
Regardless of the application used other than Microsoft Office, when your electronic 
artwork is finalized, please 'Save as' or convert the images to one of the following 
formats (note the resolution requirements for line drawings, halftones, and 
line/halftone combinations given below):  
EPS (or PDF): Vector drawings, embed all used fonts.  
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TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 
300 dpi.  
TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a 
minimum of 1000 dpi.  
TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to 
a minimum of 500 dpi. 
Please do not:  
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these 
typically have a low number of pixels and limited set of colors;  
• Supply files that are too low in resolution;  
• Submit graphics that are disproportionately large for the content. 
Color artwork  
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), 
EPS (or PDF), or MS Office files) and with the correct resolution. If, together with 
your accepted article, you submit usable color figures then Elsevier will ensure, at no 
additional charge, that these figures will appear in color online (e.g., ScienceDirect 
and other sites) regardless of whether or not these illustrations are reproduced in 
color in the printed version. For color reproduction in print, you will receive 
information regarding the costs from Elsevier after receipt of your accepted 
article. Please indicate your preference for color: in print or online only. Further 
information on the preparation of electronic artwork. 
Illustration services  
Elsevier's WebShop offers Illustration Services to authors preparing to submit a 
manuscript but concerned about the quality of the images accompanying their article. 
Elsevier's expert illustrators can produce scientific, technical and medical-style 
images, as well as a full range of charts, tables and graphs. Image 'polishing' is also 
available, where our illustrators take your image(s) and improve them to a 
professional standard. Please visit the website to find out more. 
Figure captions  
Ensure that each illustration has a caption. Supply captions separately, not attached 
to the figure. A caption should comprise a brief title (not on the figure itself) and a 
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but explain all symbols and abbreviations used. 
Tables  
 
Please submit tables as editable text and not as images. Tables can be placed either 
next to the relevant text in the article, or on separate page(s) at the end. Number 
tables consecutively in accordance with their appearance in the text and place any 
table notes below the table body. Be sparing in the use of tables and ensure that the 
data presented in them do not duplicate results described elsewhere in the article. 
Please avoid using vertical rules. 
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